Pluristem Granted U.S. Patent

Pluristem Therapeutics Inc., a developer of placenta-based cell therapy products, has been issued patent #9,096,827 titled “Adherent Cells From Placenta Tissue and Use Thereof in Therapy” from the U.S. Patent and Trademark Office.

The patent protects specific methods of culturing placental adherent stromal cells, and use of these cells for the treatment of a wide variety of diseases. Indications covered by the patent include a wide range of ischemic conditions such as heart disease, stroke, peripheral arterial disease, which includes critical limb ischemia and intermittent claudication, graft-versus-host disease, solid organ transplantation, hematopoietic stem cell transplantation, diabetes, autoimmune diseases, neuropathic pain and cancer.

“The U.S. is a very significant market for us and the protection of our IP in this market is a top priority for us. We are pleased to have been granted this patent covering both manufacturing methods and treatment indications. This patent contributes to our IP position we are building in the U.S. to support our clinical development strategy and future manufacturing and marketing in the U.S.,” said Pluristem chief executive officer, Zami Aberman.

Pluristem has been issued over 40 patents worldwide, and has approximately 150 more patents pending.